Comparison · NCT01457846-sae
AZD4547 vs Paclitaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AZD4547 vs Paclitaxel: serious adverse events. Trial comparisons, record NCT01457846-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01457846-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.2 | 0.105 | 0.348 | wilson | |
| Risk in group 2 | 0.222 | 0.106 | 0.408 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0222 | -0.23 | 0.166 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.352 | 2.3 | log | |
| Odds ratio, group 1 over group 2 | 0.875 | 0.265 | 2.89 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on AZD4547 than on Paclitaxel | 45 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AZD4547 | 80mg BD 2 weeks on/1 week off | 8 | 40 | EG000 |
| Group 2 | Paclitaxel | 80mg / m\^2 | 6 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
AEs will be collected throughout the study, from randomisation until the end of the follow-up period. The follow-up period is defined as 28 days after study treatment (AZD4547 or paclitaxel) is discontinued.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
- NCT number
- NCT01457846
- Phases
- PHASE2
- Conditions
- Gastro-oesophageal Junction Cancer, Gastric Cancer
- Interventions
- AZD4547, paclitaxel
- Lead sponsor
- AstraZeneca
- Results first posted
- 2017-03-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01457846?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01457846-sae